Aldeyra Therapeutics
Develops RASP modulators and ophthalmology candidates for immune-mediated diseases.
$1.51
After-hours close+0.03 (+1.68%)
At close$1.49(−3.57%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 61.90%37.34M sharesInsiders 3.56%2.15M sharesOther 34.54%20.84M shares
Shares outstanding 60.32M · Float 52.68M · 87.3% free float
Institutions13F, as of Mar 31, 2026
135 holders · 37.34M shares · 23 new positions · 74 increased · 37 reduced · 33 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Knoll Capital Management, LLC | 5.48M | 9.08% | 0 | May 15, 2026 |
| BlackRock, Inc. | 3.76M | 6.24% | −86.2K | May 13, 2026 |
| AQR Capital Management LLC | 2.83M | 4.69% | +1.60M | May 15, 2026 |
| Vanguard Capital Management LLC | 2.36M | 3.92% | +2.36Mnew | May 15, 2026 |
| Kingdon Capital Management, L.L.C. | 2.15M | 3.57% | +302.3K | May 15, 2026 |
| 683 Capital Management, LLC | 1.50M | 2.49% | −30.0K | May 15, 2026 |
| D. E. Shaw & Co., Inc. | 1.40M | 2.33% | −197.3K | May 15, 2026 |
| Geode Capital Management, LLC | 1.25M | 2.07% | +81.1K | May 15, 2026 |
Beneficial owners13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Perceptive Advisors LLC | 10 percent owner | 5.88M | 9.74% | Apr 7, 2025 |
| Todd C. Brady | director, officer: President and CEO | 1.72M | 2.85% | Jun 5, 2026 |
| Stephen Machatha | officer: Chief Development Officer | 221.8K | 0.37% | Aug 13, 2025 |
| Richard Douglas | director | 195.0K | 0.32% | Mar 20, 2026 |
| Michael Alfieri | officer: Principal Financial Officer | 7.5K | 0.01% | Mar 19, 2026 |
6 ten-percent owners hold 9.60M shares by Form 4, outside the officers-and-directors figure above · 13 people have not refiled in the last 18 months (12.14M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jun 3, 2026 | Todd C. Bradydirector, officer: President and CEO | Purchase | 250,000 | $1.67 | 1,721,298 |
| Mar 19, 2026 | Richard Douglasdirector | Purchase | 70,000 | $1.40 | 195,000 |
| Mar 18, 2026 | Michael Alfieriofficer: Principal Financial Officer | Purchase | 5,000 | $1.42 | 7,500 |
CongressHouse and Senate disclosures
Not reported.